Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=31929 Lorus Therapeutics Announces Dramatic Anti-Tumor Results For GTI 2040 - GTI 2040 demonstrates complete regressions in in vivo combination studies - ******* make sure you check out the biography section of the company website ********* TORONTO--(BUSINESS WIRE)--Nov. 22, 1999-- Lorus Therapeutics Inc.(TSE: LOR.) (ME: LOR.) (OTC Bulletin Board: LORFF) ("Lorus") today announced dramatic results of recent anti-tumor studies with GTI 2040, including complete tumor regressions, when used in combination with certain chemotherapeutic agents. The results were based on in vivo studies performed using recognized human kidney cancer, colon cancer and melanoma models. The studies were performed at the Company's research facilities at the Sunnybrook Health Science Centre in Toronto, Canada and have been confirmed through repeat experiments. Lorus reported that when SCID mice bearing a human kidney cancer line were treated with a combination of GTI 2040 and two commonly used chemotherapy drugs (5-fluorouracil or vinblastine), complete tumor regression was observed in all the mice treated. The Company also reported that similar tumor regressions were observed in studies combining GTI 2040 and another commonly used chemotherapy drug, mitomycin C in in vivo mouse models of human melanoma and human colon cancer. GTI 2040 also significantly enhanced the anti-tumor effects of other well-known anti-cancer drugs such as gemcitabine, estramustine and paclitaxel in a standard human colon carcinoma mouse model. "We already know that GTI 2040 performs extremely well when used alone, however, these results demonstrate that GTI 2040 has even more striking anti-cancer properties when used in combination with established chemotherapeutic agents", said Philippe G. Lacaille, CEO at Lorus. "Complete regression of tumors is rare but it remains the ultimate goal of any new anti-cancer drug. These results could be very significant to patients with these diseases because of the dramatic effects GTI 2040 has shown in combination with widely used chemotherapeutic drugs. We are extremely encouraged by these results and we look forward to starting our clinical trials as soon as possible." Lorus announced on November 16, 1999 that it had filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the Company's anti-cancer drug, GTI 2040. In its press release, the Company reported that GTI 2040 had demonstrated exceptionally strong anti-tumor properties when tested with a wide range of human tumors in animal models, including tumors derived from lung, breast, colon, liver, ovary, kidney and pancreas. Lorus is a biopharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing pro...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=3192938013210